genomiQa has announced a new Brisbane-based validation study of its CapeDX whole-genome analysis platform in a partnership with Icon Group.
genomiQa is a spin-off company from the QIMR Berghofer Medical Research Institute. it is focused on developing precision whole-genome analytics.
Its CapeDX platform supports the personalisation of a patient’s cancer treatment by analysing the whole genome of the patient and their cancer tumour.
The company said the pilot study will be conducted in collaboration with Icon Cancer Centre Wesley – part of the global Icon Group – and will involve genomic testing of up to 15 patients.
Based on genomiQa’s analysis of the patients’ genomes, each patient may be matched to the most suitable treatment option for their cancer, including approved drugs and those available through clinical trials.
According to genomiQa CEO Colin Albert, the validation study was a major step towards rolling out the company’s precision analytics platform more widely.
“Through this pilot study, we will validate genomiQa’s offerings and service delivery,” said Mr Albert.
“Our partnership with Icon Group is essential to the success of the project, and the fact that Icon has a rich history of supporting world leading research is a key benefit.”
Icon Group’s director of research, Dr John Bashford, said, “We are delighted to offer patients the opportunity to access this Australian-first study and ensure treatment is personalised to their unique genomic information.
“No other technique currently simultaneously examines the hereditary drivers of cancers as well as more than 1500 known cancer genes in a tumour.”
This project is supported by the Australian Department of Industry, Science, Energy and Resources through the Entrepreneurs’ Programme. It has contributed nearly $500,000 of matched funding.
Additional funding was provided by QIMR Berghofer Medical Research Institute.